| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.4 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.054 | 0.4 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.048 | 0.4 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.4 |